1. In Vivo
  2. >>Business Strategy

Jomed Stakes Out the US

By all accounts, the one piece missing from the puzzle for Jomed NV, the small European supplier making waves in the highly competitive field of interventional cardiology, has been a US presence. Thus, most industry observers saw the value in Jomed's merger with Endosonics as providing it with a US sales and marketing infrastructure.

By all accounts the one piece missing from the puzzle for Jomed NV , the small European supplier making waves in the highly competitive field of interventional cardiology, has been a US presence. Having successfully established itself in Europe and fresh on the heels of a well-received IPO, Jomed officials have known for years that they would, eventually, have to meet the companies it competes against in Europe, companies such as Guidant Corp. , Boston Scientific Corp. , and the Avecor Cardiovascular Inc. subsidiary of Medtronic Inc. , on their home turf. (See "Jomed's Rising Star," IN VIVO, April 1999 [A#1999800093.)

Thus, most industry observers saw the value of Jomed's deal for EndoSonics Corp. not in the latter's interventional ultrasound...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By David Wild

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

AI In Drug Discovery: The Patent Implications

 
• By David Wild

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By Marina Hickson

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

More from In Vivo

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

Rising Leaders 2025: Ovid’s Meg Alexander On Neurology’s Next Frontier

 
• By Jo Shorthouse

Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.